These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Ertekin-Taner N; Graff-Radford N; Younkin LH; Eckman C; Baker M; Adamson J; Ronald J; Blangero J; Hutton M; Younkin SG Science; 2000 Dec; 290(5500):2303-4. PubMed ID: 11125143 [TBL] [Abstract][Full Text] [Related]
3. Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. De Jonghe C; Cras P; Vanderstichele H; Cruts M; Vanderhoeven I; Smouts I; Vanmechelen E; Martin JJ; Hendriks L; Van Broeckhoven C Neurobiol Dis; 1999 Aug; 6(4):280-7. PubMed ID: 10448055 [TBL] [Abstract][Full Text] [Related]
5. Increased amyloid beta protein levels in children and adolescents with Down syndrome. Mehta PD; Capone G; Jewell A; Freedland RL J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850 [TBL] [Abstract][Full Text] [Related]
6. Genetic association of CTNNA3 with late-onset Alzheimer's disease in females. Miyashita A; Arai H; Asada T; Imagawa M; Matsubara E; Shoji M; Higuchi S; Urakami K; Kakita A; Takahashi H; Toyabe S; Akazawa K; Kanazawa I; Ihara Y; Kuwano R; Hum Mol Genet; 2007 Dec; 16(23):2854-69. PubMed ID: 17761686 [TBL] [Abstract][Full Text] [Related]
7. Amyloid beta concentrations in older people with Down syndrome and dementia. Jones EL; Hanney M; Francis PT; Ballard CG Neurosci Lett; 2009 Feb; 451(2):162-4. PubMed ID: 19111900 [TBL] [Abstract][Full Text] [Related]
8. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Fukumoto H; Tennis M; Locascio JJ; Hyman BT; Growdon JH; Irizarry MC Arch Neurol; 2003 Jul; 60(7):958-64. PubMed ID: 12873852 [TBL] [Abstract][Full Text] [Related]
9. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571 [TBL] [Abstract][Full Text] [Related]
10. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377 [TBL] [Abstract][Full Text] [Related]
11. Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. Shimojo M; Sahara N; Murayama M; Ichinose H; Takashima A Neurosci Res; 2007 Mar; 57(3):446-53. PubMed ID: 17210196 [TBL] [Abstract][Full Text] [Related]
12. A multigenerational pedigree of late-onset Alzheimer's disease implies new genetic causes. Jimenez-Escrig A; Gomez-Tortosa E; Baron M; Rabano A; Arcos-Burgos M; Palacios LG; Yusta A; Anta P; Perez I; Hierro M; Munoz DG; Barquero S Brain; 2005 Jul; 128(Pt 7):1707-15. PubMed ID: 15843424 [TBL] [Abstract][Full Text] [Related]
13. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Duering M; Grimm MO; Grimm HS; Schröder J; Hartmann T Neurobiol Aging; 2005 Jun; 26(6):785-8. PubMed ID: 15718035 [TBL] [Abstract][Full Text] [Related]
14. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Matsubara E; Ghiso J; Frangione B; Amari M; Tomidokoro Y; Ikeda Y; Harigaya Y; Okamoto K; Shoji M Ann Neurol; 1999 Apr; 45(4):537-41. PubMed ID: 10211483 [TBL] [Abstract][Full Text] [Related]
16. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622 [TBL] [Abstract][Full Text] [Related]
17. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort. Blasko I; Jungwirth S; Jellinger K; Kemmler G; Krampla W; Weissgram S; Wichart I; Tragl KH; Hinterhuber H; Fischer P J Psychiatr Res; 2008 Sep; 42(11):946-55. PubMed ID: 18155247 [TBL] [Abstract][Full Text] [Related]
18. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level. Pesaresi M; Batelli S; Prato F; Polito L; Lovati C; Scarpini E; Quadri P; Mariani C; Albani D; Forloni G Neurobiol Dis; 2007 Mar; 25(3):609-13. PubMed ID: 17174555 [TBL] [Abstract][Full Text] [Related]
19. Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression. Krezowski J; Knudson D; Ebeling C; Pitstick R; Giri RK; Schenk D; Westaway D; Younkin L; Younkin SG; Ashe KH; Carlson GA Hum Mol Genet; 2004 Sep; 13(18):1989-97. PubMed ID: 15254013 [TBL] [Abstract][Full Text] [Related]
20. Increased serum neopterin levels in adults with Down syndrome. Mehta PD; Patrick BA; Dalton AJ; Patel B; Mehta SP; Pirttila T; Coyle PK J Neuroimmunol; 2005 Jul; 164(1-2):129-33. PubMed ID: 15908015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]